In October, Oxular began a phase 2 trial for its therapeutic candidate OXU-001, for treatment of diabetic macular edema ...

A new study 1 from Turkey reported that during the acute phase of the COVID-19 infection, the retinal vascularity and perfusion of the retina decreases and the foveal avascular zone (FAZ) expands. The ...

EYLEA’s unique MoA: What is the rationale for the higher molar dose?

The company offers year-round educational services on the conditions, using this month in particular to guide patients to ...

The Sentinel Camera aims to address critical gaps in retinal disease screening by offering a portable device that captures high-quality images that require no dilation of the eye.

KIO-30 is a small molecule photoswitch that selectively confers light-sensing capabilities to retinal ganglion cells following the degeneration of photoreceptors in inherited retinal diseases.

Panelists discuss how careful patient selection and management of potential complications - including surgical risks, device-related adverse events, and cost-benefit considerations requiring operating ...

Panelists discuss how ideal candidates for aflibercept 8 mg include patients with stable disease on current anti-VEGF therapy who seek reduced treatment burden, newly diagnosed patients, and those ...

Previous research has shown that voretigene neparvovec administered subretinally early in childhood for RPE65-mediated inherited retinal dystrophy achieved encouraging efficacious results. Treatment ...

Panelists discuss how faricimab’s bispecific antibody design uniquely targets both VEGF-A and Ang-2 pathways, addressing the complementary role of Ang-2 in vascular destabilization and inflammation in ...

Panelists discuss how novel intravitreal agents faricimab and high-dose aflibercept 8mg offer potential advantages in treating retinal diseases through their extended durability and dual mechanism of ...